0001209191-23-031509.txt : 20230522
0001209191-23-031509.hdr.sgml : 20230522
20230522170246
ACCESSION NUMBER: 0001209191-23-031509
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230518
FILED AS OF DATE: 20230522
DATE AS OF CHANGE: 20230522
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Levin Andrew David
CENTRAL INDEX KEY: 0001867539
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40708
FILM NUMBER: 23945420
MAIL ADDRESS:
STREET 1: C/O ELIEM THERAPEUTICS, INC.
STREET 2: 23515 NE NOVELTY HILL RD, STE B221 #125
CITY: REDMOND
STATE: WA
ZIP: 98053
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Eliem Therapeutics, Inc.
CENTRAL INDEX KEY: 0001768446
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 832273741
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 23515 NE NOVELTY HILL ROAD
STREET 2: SUITE B221 #125
CITY: REDMOND
STATE: WA
ZIP: 98053
BUSINESS PHONE: 877-354-3689
MAIL ADDRESS:
STREET 1: 23515 NE NOVELTY HILL ROAD
STREET 2: SUITE B221 #125
CITY: REDMOND
STATE: WA
ZIP: 98053
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-05-18
0
0001768446
Eliem Therapeutics, Inc.
ELYM
0001867539
Levin Andrew David
C/O ELIEM THERAPEUTICS, INC.
23515 NE NOVELTY HILL RD, STE. B221 #125
REDMOND
WA
98053
1
1
0
0
Executive Chairman
0
Stock Option (Right To Buy)
3.00
2023-05-18
4
A
0
10000
0.00
A
2033-05-17
Common Stock
10000
10000
D
The shares subject to the option will vest on the earlier of May 18, 2024 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.
Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.
/s/ Brian Woodard, Attorney-in-Fact
2023-05-22